8-K filing — Lipocine Inc. (LPCN)
Filed: 2026-09-16 AccNo: 0001493152-26-042933 Size: 11 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Lipocine Announces Initiation Of Phase 3 BLOOM Study Of Oral Brexanolone LPCN 1154 In Postpartum Depression, Planning About 120 Participants; First Dosing Expected Early Q4 2026
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K/A filing — Lipocine Inc. (LPCN)
Filed: 2026-08-21 AccNo: 0001493152-26-039689 Size: 257 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Lipocine Q2 EPS $(0.32) Beats $(0.43) Estimate, Sales $190.099K Beat $156.500K Estimate
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.43) by 25.58 percent. This is a 21.95 percent increase over losses of $(0.41) per share from the